CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ExtremoChem develops synthetic small organic molecules that stabilize biopharmaceuticals, particularly monoclonal antibodies. These compounds enhance the stability of proteins during production and storage, reducing degradation and allowing for long-term storage without refrigeration.
Biologics are medical drugs produced using biotechnology, other than direct extraction from a native biological source.
Many of biopharmaceutical products are subject to very strict production, storage and distribution requirements in order to preserve effectiveness and safety.
Biopharmaceuticals stability is a key issue in assuring that these medicines maintain their quality, safety and full potency.
Once potency is lost, it cannot be restored, this means the biologic is wasted.
ExtremoChem sy…
EXTREMOCHEM LDA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
